Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBH589 in Refractory Clear Cell Renal Carcinoma
NCT00550277Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in renal cell carcinoma (RCC), sponsored by SCRI Development Innovations. Primary endpoint: Progression-free Survival at 18 months. Started Jan 2008; status: completed.
02
Drugs
panobinostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00550277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550277.